Aroylsemicarbazide derivatives against thromboembolic diseases

ABSTRACT

Novel compounds of the formula (I) in which Het, R 1 , R 2  and R 3  have the meaning indicated in Patent claim  1 , are inhibitors of coagulation factor Xa and can be employed for the prophylaxis and/or therapy of thromboembolic diseases and for the treatment of tumors.

This application is a 371 of PCT/EP04/05088, filed May 12, 2004.

The invention relates to compounds of the formula I

in which

-   Het denotes a mono- or bicyclic aromatic heterocyclic radical having     from 1 to 3 N, O and/or S atoms which is mono- or disubstituted by     Hal, -   R¹ denotes A, which may be mono-, di- or trisubstituted by     S(O)_(m)A, Ph, NH₂, NHA, NA₂, OH, OA, PO(OA)₂, ethynyl, vinyl or     O(CH₂)_(n)Ph, -   R² denotes H, Hal or A, -   R³ denotes 2-oxopiperidin-1-yl, 2-oxopyrrolidin-1-yl,     2-oxo-1H-pyridin-1-yl, 3-oxomorpholin-4-yl, 4-oxo-1H-pyridin-1-yl,     2-oxo-1H-pyrazin-1-yl, 2-oxoimidazolid in-1-yl, 2-iminopiperid     in-1-yl, 2-iminopyrrolidin-1-yl, 3-iminomorpholin-4-yl,     2-iminoimidazolidin-1-yl, 2-imino-1H-pyrazin-1-yl,     2,6-dioxopiperidin-1-yl, 2-oxopiperazin-1-yl,     2,6-dioxopiperazin-1-yl, 2,5-dioxopyrrolid in-1-yl,     2-oxo-1,3-oxazolidin-3-yl, 3-oxo-2H-pyridazin-2-yl,     2-caprolactam-1-yl (=2-oxoazepan-1-yl),     2-azabicyclo[2.2.2]octan-3-on-2-yl,     5,6-dihydro-1H-pyrimidin-2-oxo-1-yl, 2-oxo-1,3-oxazinan-3-yl or     4H-1,4-oxazin4-yl, -   A denotes H, unbranched, branched or cyclic alkyl having 1-10 C     atoms, -   Ph denotes phenyl, -   Hal denotes F, Cl, Br or I, -   n denotes 1, 2, 3, 4, 5 or 6, -   m denotes 0, 1 or 2,     and pharmaceutically usable derivatives, solvates, salts and     stereoisomers thereof, including mixtures thereof in all ratios.

The invention had the object of finding novel compounds having valuable properties, in particular those which can be used for the preparation of medicaments.

It has been found that the compounds of the formula I and salts thereof have very valuable pharmacological properties and are well tolerated. In particular, they exhibit factor Xa-inhibiting properties and can therefore be employed for combating and preventing thromboembolic diseases, such as thrombosis, myocardial infarction, arteriosclerosis, inflammation, apoplexy, angina pectoris, restenosis after angioplasty and claudicatio intermittens.

The compounds of the formula I according to the invention may furthermore be inhibitors of the coagulation factors factor VIIa, factor IXa and thrombin in the blood coagulation cascade.

Aromatic amidine derivatives having an antithrombotic action are disclosed, for example, in EP 0 540 051 B1, WO 98/28269, WO 00/71508, WO 00/71511, WO 00/71493, WO 00/71507, WO 00/71509, WO 00/71512, WO 00/71515 and WO 00/71516. Cyclic guanidines for the treatment of thromboembolic diseases are described, for example, in WO 97/08165. Aromatic heterocyclic compounds having a factor Xa inhibitory activity are disclosed, for example, in WO 96/10022. Substituted N-[(aminoiminomethyl)phenylalkyl]azaheterocyclylamides as factor Xa inhibitors are described in WO 96/40679.

Regioisomeric compounds of the derivatives according to the invention are described in DE 10040783.8 (compounds of the formula 7 in synthesis scheme 1).

The antithrombotic and anticoagulant effect of the compounds according to the invention is attributed to the inhibitory action against activated coagulation protease, known by the name factor Xa, or to the inhibition of other activated serine proteases, such as factor VIIa, factor IXa or thrombin.

Factor Xa is one of the proteases involved in the complex process of blood coagulation. Factor Xa catalyses the conversion of prothrombin into thrombin. Thrombin cleaves fibrinogen into fibrin monomers, which, after cross-linking, make an elementary contribution to thrombus formation. Activation of thrombin may result in the occurrence of thromboembolic diseases. However, inhibition of thrombin may inhibit the fibrin formation involved in thrombus formation.

The inhibition of thrombin can be measured, for example by the method of G. F. Cousins et al. in Circulation 1996, 94, 1705-1712.

Inhibition of factor Xa can thus prevent the formation of thrombin. The compounds of the formula I according to the invention and salts thereof engage in the blood coagulation process by inhibiting factor Xa and thus inhibit the formation of thrombi.

The inhibition of factor Xa by the compounds according to the invention and the measurement of the anticoagulant and antithrombotic activity can be determined by conventional in-vitro or in-vivo methods. A suitable method is described, for example, by J. Hauptmann et al. in Thrombosis and Haemostasis 1990, 63, 220-223.

The inhibition of factor Xa can be measured, for example by the method of T. Hara et al. in Thromb. Haemostas. 1994, 71, 314-319.

Coagulation factor VIIa initiates the extrinsic part of the coagulation cascade after binding to tissue factor and contributes to the activation of factor X to give factor Xa. Inhibition of factor VIIa thus prevents the formation of factor Xa and thus subsequent thrombin formation.

The inhibition of factor VIIa by the compounds according to the invention and the measurement of the anticoagulant and antithrombotic activity can be determined by conventional in-vitro or in-vivo methods. A conventional method for the measurement of the inhibition of factor VIIa is described, for example, by H. F. Ronning et al. in Thrombosis Research 1996, 84, 73-81.

Coagulation factor IXa is generated in the intrinsic coagulation cascade and is likewise involved in the activation of factor X to give factor Xa. Inhibition of factor IXa can therefore prevent the formation of factor Xa in a different way.

The inhibition of factor IXa by the compounds according to the invention and the measurement of the anticoagulant and antithrombotic activity can be determined by conventional in-vitro or in-vivo methods. A suitable method is described, for example, by J. Chang et al. in Journal of Biological Chemistry 1998, 273, 12089-12094.

The compounds according to the invention may furthermore be used for the treatment of tumours, tumour diseases and/or tumour metastases. A correlation between tissue factor TF/factor VIIa and the development of various types of cancer has been indicated by T. Taniguchi and N. R. Lemoine in Biomed. Health Res. (2000), 41 (Molecular Pathogenesis of Pancreatic Cancer), 57-59.

The publications listed below describe an antitumoral action of TF-VII and factor Xa inhibitors for various types of tumour:

-   K. M. Donnelly et al. in Thromb. Haemost. 1998; 79: 1041-1047; -   E. G. Fischer et al. in J. Clin. Invest. 104: 1213-1221 (1999); -   B. M. Mueller et al. in J. Clin. Invest. 101: 1372-1378 (1998); -   M. E. Bromberg et al. in Thromb. Haemost. 1999; 82: 88-92.

The compounds of the formula I can be employed as medicament active ingredients in human and veterinary medicine, in particular for the treatment and prevention of thromboembolic diseases, such as thrombosis, myocardial infarction, arteriosclerosis, inflammation, apoplexy, angina pectoris, restenosis after angioplasty, claudicatio intermittens, venous thrombosis, pulmonary embolism, arterial thrombosis, myocardial ischaemia, unstable angina and strokes based on thrombosis.

The compounds according to the invention are also employed for the treatment or prophylaxis of atherosclerotic diseases, such as coronary arterial disease, cerebral arterial disease or peripheral arterial disease.

The compounds are also employed in combination with other thrombolytic agents in myocardial infarction, furthermore for prophylaxis for reocclusion after thrombolysis, percutaneous transluminal angioplasty (PTCA) and coronary bypass operations.

The compounds according to the invention are furthermore used for the prevention of rethrombosis in microsurgery, furthermore as anticoagulants in connection with artificial organs or in haemodialysis.

The compounds are furthermore used in the cleaning of catheters and medical aids in patients in vivo, or as anticoagulants for the preservation of blood, plasma and other blood products in vitro. The compounds according to the invention are furthermore used for diseases in which blood coagulation makes a crucial contribution toward the course of the disease or represents a source of secondary pathology, such as, for example, in cancer, including metastasis, inflammatory diseases, including arthritis, and diabetes.

The compounds according to the invention are furthermore used for the treatment of migraine (F. Morales-Asin et al., Headache, 40, 2000, 4547).

In the treatment of the diseases described, the compounds according to the invention are also employed in combination with other thrombolytically active compounds, such as, for example, with the “tissue plasminogen activator” t-PA, modified t-PA, streptokinase or urokinase. The compounds according to the invention are administered either at the same time as or before or after the other substances mentioned.

Particular preference is given to simultaneous administration with aspirin in order to prevent recurrence of the thrombus formation.

The compounds according to the invention are also used in combination with blood platelet glycoprotein receptor (IIb/IIIa) antagonists, which inhibit blood platelet aggregation.

The invention relates to the compounds of the formula I and salts thereof and to a process for the preparation of compounds of the formula I according to Claims 1-9 and pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, characterised in that

a) a compound of the formula II

in which

-   R¹, R² and R³ have the meaning indicated in claim 1, -   is reacted with a compound of the formula III     Het-CO-L  III     in which -   L denotes Cl, Br, I or a free or reactively functionally modified OH     group, and -   Het has the meaning indicated in Claim 1,     and/or     a base or acid of the formula I is converted into one of its salts.

The invention also relates to the optically active forms (stereoisomers), the enantiomers, the racemates, the diastereomers and the hydrates and solvates of these compounds. The term “solvates of the compounds” is taken to mean adductions of inert solvent molecules onto the compounds which form owing to their mutual attractive force. Solvates are, for example, mono- or dihydrates or alcoholates.

The term “pharmaceutically usable derivatives” is taken to mean, for example, the salts of the compounds according to the invention and so-called prodrug compounds.

The term “prodrug derivatives” is taken to mean compounds of the formula I which have been modified with, for example, alkyl or acyl groups, sugars or oligopeptides and which are rapidly cleaved in the organism to form the active compounds according to the invention.

These also include biodegradable polymer derivatives of the compounds according to the invention, as described, for example, in Int. J. Pharm. 115, 61-67 (1995).

The invention also relates to mixtures of the compounds of the formula I according to the invention, for example mixtures of two diastereomers, for example in the ratio 1:1, 1:2, 1:3, 1:4, 1:5, 1:10, 1:100 or 1:1000.

These are particularly preferably mixtures of stereoisomeric compounds.

For all radicals which occur more than once, such as, for example, A, their meanings are independent of one another.

Above and below, the radicals or parameters R, R¹, R² and R³ are as defined under the formula I, unless expressly stated otherwise.

A denotes alkyl, is unbranched (linear), branched or cyclic and has 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 C atoms. A preferably denotes methyl, furthermore ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl or tert-butyl, furthermore also pentyl, 1-, 2- or 3-methylbutyl, 1,1-, 1,2- or 2,2-dimethylpropyl, 1-ethylpropyl, hexyl, 1-, 2-, 3- or 4-methylpentyl, 1,1-, 1,2-, 1,3-, 2,2-, 2,3- or 3,3-dimethylbutyl, 1- or 2-ethylbutyl, 1-ethyl-1-methylpropyl, 1-ethyl-2-methylpropyl, 1,1,2- or 1,2,2-trimethylpropyl or cyclopropylmethyl, furthermore preferably, for example, trifluoromethyl.

A very particularly preferably denotes alkyl having 1, 2, 3, 4, 5 or 6 C atoms, preferably methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, hexyl, cyclopentyl, cyclohexyl, cyclopropylmethyl or trifluoromethyl.

Cyclic alkyl preferably denotes cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or cycloheptyl.

Hal preferably denotes F, Cl or Br, but also I.

Het, independently of the substitution by Hal, denotes, for example, 2- or 3-furyl, 2- or 3-thienyl, 1-, 2- or 3-pyrrolyl, 1-, 2-, 4- or 5-imidazolyl, 1-, 3-, 4- or 5-pyrazolyl, 2-, 4- or 5-oxazolyl, 3-, 4- or 5-isoxazolyl, 2-, 4- or 5-thiazolyl, 3-, 4- or 5-isothiazolyl, 2-, 3- or 4-pyridyl, 2-, 4-, 5- or 6-pyrimidinyl, furthermore preferably 1,2,3-triazol-1-, 4- or -5-yl, 1,2,4-triazol-1 -, -3- or -5-yl, 1- or 5-tetrazolyl, 1,2,3-oxadiazol-4- or -5-yl, 1,2,4-oxadiazol-3- or -5-yl, 1,3,4-thiadiazol-2- or -5-yl, 1,2,4-thiadiazol-3- or -5-yl, 1,2,3-thiadizaol-4- or -5-yl, 3- or 4-pyridazinyl, pyrazinyl, 1-, 2-, 3-, 4-, 5-, 6- or 7-indolyl, 4- or 5-isoindolyl, 1-, 2-, 4- or 5-benzimidazolyl, 1-, 3-, 4-, 5-, 6- or 7-benzopyrazolyl, 2-, 4-, 5-, 6- or 7-benzoxazolyl, 3-, 4-, 5-, 6- or 7-benzisoxazolyl, 2-, 4-, 5-, 6- or 7-benzothiazolyl, 2-, 4-, 5-, 6- or 7-benzisothiazolyl, 4-, 5-, 6- or 7-benz-2,1,3-oxadiazolyl, 2-, 3-, 4-, 5-, 6-, 7- or 8-quinolyl, 1-, 3-, 4-, 5-, 6-, 7- or 8-isoquinolyl, 3-, 4-, 5-, 6-, 7- or 8-cinn-linyl, 2-, 4-, 5-, 6-, 7- or 8-quinazolinyl, 5- or 6-quinoxalinyl, 2-, 3-, 5-, 6-, 7- or 8-2H-benzo-1,4-oxazinyl, furthermore preferably 1,3-benzodioxol-5-yl, 1,4-benzodioxan-6-yl, 2,1,3-benzothiadiazol-4- or -5-yl or 2,1,3-benzoxadiazol-5-yl.

Het particularly preferably denotes thienyl, furyl, pyrrolyl, benzofuranyl, benzo[b]thienyl, thiazolyl or oxazolyl, each of which is mono- or disubstituted by Hal.

R¹ preferably denotes alkyl having 1, 2, 3, 4, 5 or 6 C atoms, which may be substituted by S(O)_(m)A, for example SO₂CH₃, by NH₂, NHA, for example NHCH₃, by NA₂, for example N(CH₃)₂, by OH, OA, for example OCH₃, by PO(OA)₂, for example PO(OCH₃)₂, by ethynyl, phenyl, vinyl or O(CH₂)_(n)Ph.

R¹ particularly preferably denotes alkyl having 1, 2, 3, 4, 5 or 6 C atoms, which may be substituted by ethynyl, phenyl, OH or OA.

R² preferably denotes, for example, H, methyl or F.

R³ preferably denotes 2-oxopiperidin-1-yl, 2-oxopyrrolidin-1-yl, 2-oxo-1H-pyridin-1-yl, 3-oxomorpholin4-yl, 4-oxo-1H-pyridin-1-yl, 2-oxo-1H-pyrazin-1-yl, 2-oxoimidazolidin-1-yl, 2-iminopiperidin-1-yl, 2-iminopyrrolidin-1-yl, 3-iminomorpholin4-yl, 2-iminoimidazolidin-1-yl, 2-imino-1H-pyrazin-1-yl, 2-oxopiperazin-1-yl or 3-oxo-2H-pyridazin-2-yl.

The compounds of the formula I can have one or more centres of chirality and can therefore occur in various stereoisomeric forms. The formula I covers all these forms.

Accordingly, the invention relates, in particular, to the compounds of the formula I in which at least one of the said radicals has one of the preferred meanings indicated above. Some preferred groups of compounds can be expressed by the following sub-formulae Ia to Ie, which conform to the formula I and in which the radicals not designated in greater detail are as defined under the formula I, but in which

-   in Ia R¹ denotes alkyl having 1, 2, 3, 4, 5 or 6 C atoms, which may     be substituted by ethynyl, phenyl, OA, OH or OA; -   in Ib R³ denotes 2-oxopiperidin-1-yl, 2-oxopyrrolidin-1-yl,     2-oxo-1H-pyridin-1-yl, 3-oxomorpholin-4-yl, 4-oxo-1H-pyridin-1-yl,     2-oxo-1H-pyrazin-1-yl, 2-oxoimidazolidin-1-yl,     2-iminopiperidin-1-yl, 2-iminopyrrolidin-1-yl,     3-iminomorpholin-4-yl, 2-iminoimidazolidin-1-yl,     2-imino-1H-pyrazin-1-yl, 2-oxopiperazin-1-yl or     3-oxo-2H-pyridazin-2-yl; -   in Ic R² denotes H, methyl or F; -   in Id Het denotes thienyl, furyl, pyrrolyl, benzofuranyl,     benzo[b]thienyl, thiazolyl or oxazolyl, each of which is mono- or     disubstituted by Hal; -   in Ie Het denotes thienyl, furyl, pyrrolyl, benzofuranyl,     benzo[b]thienyl, thiazolyl or oxazolyl, each of which is mono- or     disubstituted by Hal,     -   R¹ denotes alkyl having 1, 2, 3, 4, 5 or 6 C atoms, which may be         substituted by ethynyl, phenyl, OA, OH or OA,     -   R² denotes H, Hal or A,     -   R³ denotes 2-oxopiperidin-1-yl, 2-oxopyrrolidin-1-yl,         2-oxo-1H-pyridin-1-yl, 3-oxomorpholin4-yl,         4-oxo-1H-pyridin-1-yl, 2-oxo-1H-pyrazin-1-yl,         2-oxoimidazolidin-1-yl, 2-iminopiperidin-1-yl,         2-iminopyrrolidin-1-yl, 3-iminomorpholin-4-yl,         2-iminoimidazolidin-1-yl, 2-imino-1H-pyrazin-1-yl,         2-oxopiperazin-1-yl or 3-oxo-2H-pyridazin-2-yl,     -   A denotes H, unbranched, branched or cyclic alkyl having 1-10 C         atoms,     -   Ph denotes phenyl,     -   Hal denotes F, Cl, Br or I,     -   n denotes 1, 2, 3, 4, 5 or 6,     -   m is 0, 1 or 2;         and pharmaceutically usable derivatives, solvates, salts and         stereoisomers thereof, including mixtures thereof in all ratios.

The compounds of the formula I and also the starting materials for the preparation thereof are, in addition, prepared by methods known per se, as described in the literature (for example in the standard works, such as Houben-Weyl, Methoden der organischen Chemie [Methods of Organic Chemistry], Georg-Thieme-Verlag, Stuttgart), to be precise under reaction conditions which are known and suitable for the said reactions. Use can also be made here of variants known per se which are not mentioned here in greater detail.

If desired, the starting materials can also be formed in situ so that they are not isolated from the reaction mixture, but instead are immediately converted further into the compounds of the formula I.

Compounds of the formula I can preferably be obtained by reacting compounds of the formula II with compounds of the formula III.

The reaction is generally carried out in an inert solvent, in the presence of an acid-binding agent, preferably an alkali or alkaline earth metal hydroxide, carbonate or bicarbonate or another salt of a weak acid of the alkali or alkaline earth metals, preferably of potassium, sodium, calcium or caesium. It may also be favourable to add an organic base, such as triethylamine, dimethylaniline, pyridine or quinoline. Depending on the conditions used, the reaction time is between a few minutes and 14 days, and the reaction temperature is between about 0° and 150°, normally between 20° and 130°.

Examples of suitable inert solvents are water; hydrocarbons, such as hexane, petroleum ether, benzene, toluene or xylene; chlorinated coal water, salts substances, such as trichloroethylene, 1,2-dichloroethane, tetra-chloromethane, chloroform or dichloromethane; alcohols, such as methanol, ethanol, iso, salts propanol, n-propanol, n-butanol or tert-butanol; ethers, such as diethyl ether, diisopropyl ether, tetrahydrofuran (THF) or dioxane; glycol ethers, such as ethylene glycol monomethyl or monoethyl ether or ethylene glycol dimethyl ether (diglyme); ketones, such as acetone or butanone; amides, such as acetamide, dimethylacetamide or dimethyl-formamide (DMF); nitriles, such as acetonitrile; sulfoxides, such as dimethyl sulfoxide (DMSO); carbon disulfide; carboxylic acids, such as formic acid or acetic acid; nitro compounds, such as nitromethane or nitrobenzene; esters, such as ethyl acetate, or mixtures of the said solvents.

The starting compounds of the formulae II and III are generally known. If they are novel, however, they can be prepared by methods known per se.

In the compounds of the formula III, L is preferably Cl, Br, I or a reactively modified OH group, such as, for example, an activated ester, an imidazolide or alkylsulfonyloxy having 1-6 C atoms (preferably methylsulfonyloxy or trifluoromethylsulfonyloxy) or arylsulfonyloxy having 6-10 C atoms (preferably phenyl- or p-tolylsulfonyloxy).

Radicals of this type for activation of the carboxyl group in typical acylation reactions are described in the literature (for example in the standard works, such as Houben-Weyl, Methoden der organischen Chemie [Methods of Organic Chemistry], Georg-Thieme-Verlag, Stuttgart).

Activated esters are advantageously formed in situ, for example through addition of HOBt or N-hydroxysuccinimide.

A base of the formula I can be converted into the associated acid-addition salt using an acid, for example by reaction of equivalent amounts of the base and the acid in an inert solvent, such as ethanol, followed by evaporation. Suitable acids for this reaction are, in particular, those which give physiologically acceptable salts. Thus, it is possible to use inorganic acids, for example sulfuric acid, nitric acid, hydrohalic acids, such as hydrochloric acid or hydrobromic acid, phosphoric acids, such as orthophosphoric acid, or sulfamic acid, furthermore organic acids, in particular aliphatic, alicyclic, araliphatic, aromatic or heterocyclic monobasic or polybasic carboxylic, sulfonic or sulfuric acids, for example formic acid, acetic acid, trifluoroacetic acid, propionic acid, pivalic acid, diethylacetic acid, malonic acid, succinic acid, pimelic acid, fumaric acid, maleic acid, lactic acid, tartaric acid, malic acid, citric acid, gluconic acid, ascorbic acid, nicotinic acid, isonicotinic acid, methane- or ethanesulfonic acid, ethanedisulfonic acid, 2-hydroxyethanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, naphthalenemono- and -disulfonic acids, and laurylsulfuric acid. Salts with physiologically unacceptable acids, for example picrates, can be used for the isolation and/or purification of the compounds of the formula I.

On the other hand, compounds of the formula I can be converted into the corresponding metal salts, in particular alkali metal or alkaline earth metal salts, or into the corresponding ammonium salts using bases (for example sodium hydroxide, potassium hydroxide, sodium carbonate or potassium carbonate).

It is also possible to use physiologically acceptable organic bases, such as, for example, ethanolamine.

Compounds of the formula I according to the invention may be chiral owing to their molecular structure and may accordingly occur in various enantiomeric forms. They can therefore exist in racemic or in optically active form.

Since the pharmaceutical activity of the racemates or stereoisomers of the compounds according to the invention may differ, it may be desirable to use the enantiomers. In these cases, the end product or even the intermediates can be separated into enantiomeric compounds by chemical or physical measures known to the person skilled in the art or even employed as such in the synthesis.

In the case of racemic amines, diastereomers are formed from the mixture by reaction with an optically active resolving agent. Examples of suitable resolving agents are optically active acids, such as the R and S forms of tartaric acid, diacetyltartaric acid, dibenzoyltartaric acid, mandelic acid, malic acid, lactic acid, suitably N-protected amino acids (for example N-benzoylproline or N-benzenesulfonylproline), or the various optically active camphorsulfonic acids. Also advantageous is chromatographic enantiomer resolution with the aid of an optically active resolving agent (for example dinitrobenzoylphenylglycine, cellulose triacetate or other derivatives of carbohydrates or chirally derivatised methacrylate polymers immobilised on silica gel). Suitable eluents for this purpose are aqueous or alcoholic solvent mixtures, such as, for example, hexane/isopropanol/acetonitrile, for example in the ratio 82:15:3.

The invention furthermore relates to the use of the compounds of the formula I and/or physiologically acceptable salts thereof for the preparation of pharmaceutical compositions, in particular by non-chemical methods. They can be converted here into a suitable dosage form together with at least one solid, liquid and/or semi-liquid excipient or adjuvant and, if desired, in combination with one or more further active ingredients.

The invention furthermore relates to medicaments comprising at least one compound of the formula I and/or pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios, and, if desired, excipients and/or adjuvants.

These compositions can be used in human or veterinary medicine. Suitable excipients are organic or inorganic substances which are suitable for enteral (for example oral), parenteral or topical administration and do not react with the novel compounds, for example water, vegetable oils, benzyl alcohols, alkylene glycols, polyethylene glycols, glycerol triacetate, gelatine, carbohydrates, such as lactose or starch, magnesium stearate, talc or Vaseline. Suitable for oral administration are, in particular, tablets, pills, coated tablets, capsules, powders, granules, syrups, juices or drops, suitable for rectal administration are suppositories, suitable for parenteral administration are solutions, preferably oil-based or aqueous solutions, furthermore suspensions, emulsions or implants, and suitable for topical application are ointments, creams or powders or also as nasal sprays. The novel compounds may also be lyophilised and the resultant lyophilisates used, for example, to prepare injection preparations. The compositions indicated may be sterilised and/or comprise adjuvants, such as lubricants, preservatives, stabilisers and/or wetting agents, emulsifying agents, salts for modifying the osmotic pressure, buffer substances, colorants and flavours and/or a plurality of further active ingredients, for example one or more vitamins.

The compounds of the formula I and physiologically acceptable salts thereof can be used for combating and preventing thromboembolic diseases, such as thrombosis, myocardial infarction, arteriosclerosis, inflammation, apoplexy, angina pectoris, restenosis after angioplasty and claudicatio intermittens, migraine, tumours, tumour diseases and/or tumour metastases.

In general, the substances according to the invention are preferably administered in doses between about 1 and 500 mg, in particular between 5 and 100 mg, per dosage unit. The daily dose is preferably between about 0.02 and 10 mg/kg of body weight. However, the specific dose for each patient depends on a wide variety of factors, for example on the efficacy of the specific compound employed, on the age, body weight, general state of health, sex, on the diet, on the time and method of administration, on the excretion rate, medicament combination and severity of the particular disease to which the therapy applies. Oral administration is preferred.

The invention also relates to a set (kit) consisting of separate packs of

-   (a) an effective amount of a compound of the formula I and/or     pharmaceutically usable derivatives, solvates, salts and     stereoisomers thereof, including mixtures thereof in all ratios, and -   (b) an effective amount of a further medicament.

The set comprises suitable containers, such as boxes, individual bottles, bags or ampoules. The set may, for example, comprise separate ampoules each containing an effective amount of a compound of the formula I and/or pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios, and an effective amount of a further medicament in dissolved or lyophilised form.

The invention furthermore relates to the use of compounds of the formula I and/or pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios, for the preparation of a medicament for the treatment of thrombosis, myocardial infarction, arteriosclerosis, inflammation, apoplexy, angina pectoris, restenosis after angioplasty, claudicatio intermittens, migraine, tumours, tumour diseases and/or tumour metastases, in combination with at least one further medicament active ingredient.

Above and below, all temperatures are given in ° C. In the following examples, “conventional work-up” means that water is added if necessary, the pH is adjusted, if necessary, to between 2 and 10, depending on the constitution of the end product, the mixture is extracted with ethyl acetate or dichloromethane, the phases are separated, the organic phase is dried over sodium sulfate and evaporated, and the product is purified by chromatography on silica gel and/or by crystallisation. Rf values on silica gel; eluent: ethyl acetate/methanol 9:1.

Mass spectrometry (MS): EI (electron impact ionisation) M⁺FAB (fast atom bombardment) (M+H)⁺ESI (electrospray ionisation) (M+H)⁺ (unless stated otherwise)

EXAMPLE 1 1-(5-Chlorothien-2-ylcarbonyl)-4-[4-(3-oxomorpholin-4-yl)phenyl]-2-propylsemicarbazide is prepared analogously to the following scheme

-   1. A mixture of 2.0 g (10.4 mmol) of     4-(4-aminophenyl)morpholin-3-one 2, 2.1 g (10.4 mmol) of     4-nitrophenyl chloroformate and 0.84 ml (10.4 mmol) of pyridine in     50 ml of dichloromethane is stirred at room temperature for 1 hour.     2.04 g (10.4 mmol) of benzophenone hydrazone 1 and 5.3 ml (31.2     mmol) of ethyldiisopropylamine are added successively to this     mixture. The suspension is stirred at room temperature for 2 hours,     diluted with ethyl acetate and washed with 0.5 N sodium hydroxide     solution. The mixture is then subjected to conventional work-up,     giving 3.94 g (79%) of     1-diphenylmethylene-4-[4-(3-oxo-4-morpholinyl)phenyl]semicarbazide 3     as colourless crystals having a melting point of 241-243°; MS-EI     (M⁺)=414 (8%), 165 (100%). -   2. A suspension of 1.0 g (2.4 mmol) of the semicarbazide 3 and 0.98     g (3.0 mmol) of caesium carbonate in 30 ml of acetonitrile is     stirred at room temperature for 0.5 hour. 0.29 ml (3.0 mmol) of 1     -iodopropane is added to this mixture, which is stirred for a     further 7 hours. After 150 ml of ice-cold water have been added, a     precipitate deposits, which is subjected to conventional work-up,     giving 1.07 g (97%) of     1-diphenylmethylene-4-[4-(3-oxo-4-morpholinyl)phenyl]-2-propylsemicarbazide     4 as colourless crystals having a melting point of 75-77°; MS-EI     (M⁺)=456 (2%), 180 (100%). -   3. 5.0 ml of 37% hydrogen chloride solution are added to a solution     of 0.5 g (1.1 mmol) of the propylsemicarbazide 4 in 20 ml of     ethanol, and the mixture is stirred at room temperature for 1 hour.     After the reaction solution has been diluted with 30 ml of water, it     is subjected to conventional workup, giving 0.27 g (84%) of     4-[4-(3-oxo-4-morpholinyl)phenyl]-2-propylsemicarbazide 5 as     colourless crystals having a melting point of 127-129°; MS-EI     (M⁺)=318 (6%), 218 (100%). -   4. 100.0 mg (0.342 mmol) of the semicarbazide 5, 55.6 mg (0.342     mmol) of 5-chlorothiophene-2-carboxylic acid, 66.2 mg (0.342 mmol)     of N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride and     36.2 mg (0.342 mmol) of 1-hydroxybenzotriazole are dissolved in 10     ml of DMF, and 38.0 μl (0.342 mmol) of 4-methylmorpholine are added     at RT. After the mixture has been stirred at RT for 18 hours, it is     poured into 75 ml of ice-water and subjected to conventional     work-up, giving 77.0 mg (51.5%) of     1-(5-chlorothien-2-ylcarbonyl)-4-[4-(3-oxomorpholin-4-yl)phenyl]-2-propylsemicarbazide     (“A1”) as colourless crystals having a melting point of 101-102°;     MS-ESI (M+H⁺)=437.

The following compounds are obtained analogously

-   1-(5-chlorothien-2-ylcarbonyl)4-[3-methyl-4-(3-oxomorpholin4-yl)-phenyl]-2-(prop-2-ynyl)semicarbazide     (“A2”), -   1-(3-chloroth     ien-2-ylcarbonyl)4-[3-methyl4-(3-oxomorpholin4-yl)-phenyl]-2-benzylsemicarbazide     (“A3”), -   1-(5-bromothien-2-ylcarbonyl)-4-[3-methyl-4-(3-oxomorpholin-4-yl)-phenyl]-2-benzylsemicarbazide, -   1-(3-chlorobenzo[b]thienyl-2-ylcarbonyl)-4-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]-2-benzylsemicarbazide, -   1-(5-chlorothien-2-ylcarbonyl)-4-[3-methyl-4-(3-oxomorpholin-4-yl)-phenyl]-2-benzylsemicarbazide, -   1-(5-bromothien-2-ylcarbonyl)-4-[3-fluoro-4-(3-oxomorpholin-4-yl)-phenyl]-2-(2-methoxyethyl)semicarbazide, -   1-(3-chlorobenzo[b]thienyl-2-ylcarbonyl)-4-[3-fluoro4-(3-oxomorpholin-4-yl)phenyl]-2-(2-methoxyethyl)semicarbazide, -   1-(3-chlorothien-2-ylcarbonyl)-4-[3-fluoro-4-(3-oxomorpholin-4-yl)-phenyl]-2-(2-methoxyethyl)semicarbazide, -   1-(5-chlorothien-2-ylcarbonyl)-4-[3-fluoro-4-(3-oxomorpholin-4-yl)-phenyl]-2-(2-methoxyethyl)semicarbazide, -   1-(3-chlorothien-2-ylcarbonyl)-4-[4-(2-oxo-1H-pyrazin-     1-yl)phenyl]-2-cyclopropylmethylsemicarbazide, -   1-(3-chlorothien-2-ylcarbonyl)-4-[4-(2-oxo-1H-pyridin-1-yl)phenyl]-2-cyclopropylmethylsemicarbazide, -   1-(3-chloroth     ien-2-ylcarbonyl)-4-[3-methyl-4-(3-oxomorpholin-4-yl)-phenyl]-2-cyclopropylmethylsemicarbazide, -   1-(5-chlorothien-2-ylcarbonyl)-4-[3-methyl-4-(3-oxomorpholin-4-yl)-phenyl]-2-(2-methoxyethyl)semicarbazide, -   1-(5-chlorothien-2-ylcarbonyl)-4-[3-methyl-4-(3-oxomorpholin-4-yl)-phenyl]-2-cyclopropylmethylsemicarbazide, -   1-(5-bromothien-2-ylcarbonyl)-4-[3-methyl4-(3-oxomorpholin-4-yl)-phenyl]-2-cyclopropylmethylsemicarbazide.     Pharmacological Data     Affinity to Receptors

TABLE 1 Compound No. FXa-IC₅₀ [nM] TF/FVIIa-IC₅₀ [nM] “A1” 390.0 830.0 “A2” 570.0 1000.0 “A3” 87.0 180.0

The following examples relate to pharmaceutical compositions:

EXAMPLE A Injection Vials

A solution of 100 g of an active ingredient of the formula I and 5 g of disodium hydrogenphosphate in 3 l of bidistilled water is adjusted to pH 6.5 using 2N hydrochloric acid, sterile filtered, transferred into injection vials, lyophilised under sterile conditions and sealed under sterile conditions. Each injection vial contains 5 mg of active ingredient.

EXAMPLE B Suppositories

A mixture of 20 g of an active ingredient of the formula I with 100 g of soya lecithin and 1400 g of cocoa butter is melted, poured into moulds and allowed to cool. Each suppository contains 20 mg of active ingredient.

EXAMPLE C Solution

A solution is prepared from 1 g of an active ingredient of the formula I, 9.38 g of NaH₂PO₄.2H₂O, 28.48 g of Na₂HPO₄.12H₂O and 0.1 g of benzalkonium chloride in 940 ml of bidistilled water. The pH is adjusted to 6.8, and the solution is made up to 1 l and sterilised by irradiation. This solution can be used in the form of eye drops.

EXAMPLE D Ointment

500 mg of an active ingredient of the formula I are mixed with 99.5 g of Vaseline under aseptic conditions.

EXAMPLE E Tablets

A mixture of 1 kg of active ingredient of the formula I, 4 kg of lactose, 1.2 kg of potato starch, 0.2 kg of talc and 0.1 kg of magnesium stearate is pressed to give tablets in a conventional manner in such a way that each tablet contains 10 mg of active ingredient.

EXAMPLE F Coated Tablets

Tablets are pressed analogously to Example E and subsequently coated in a conventional manner with a coating of sucrose, potato starch, talc, tragacanth and dye.

EXAMPLE G Capsules

2 kg of active ingredient of the formula I are introduced into hard gelatine capsules in a conventional manner in such a way that each capsule contains 20 mg of the active ingredient.

EXAMPLE H Ampoules

A solution of 1 kg of active ingredient of the formula I in 60 l of bidistilled water is sterile filtered, transferred into ampoules, lyophilised under sterile conditions and sealed under sterile conditions. Each ampoule contains 10 mg of active ingredient. 

1. Compounds of the formula I

in which Het denotes a mono- or bicyclic aromatic heterocyclic radical having from 1 to 3 N, O and/or S atoms which is mono- or disubstituted by Hal, R¹ denotes A, which may be mono-, di- or trisubstituted by S(O)_(m)A, Ph, NH₂, NHA, NA₂, OH, OA, PO(OA)₂, ethynyl, vinyl or O(CH₂)_(n)Ph, R² denotes H, Hal or A, R³ denotes 2-oxopiperidin-1-yl, 2-oxopyrrolidin-1-yl, 2-oxo-1H-pyridin-1-yl, 3-oxomorpholin-4-yl, 4-oxo-1H-pyridin-1-yl, 2-oxo-1H-pyrazin-1-yl, 2-oxoimidazolidin-1-yl, 2-iminopiperidin-1-yl, 2-iminopyrrolidin-1-yl, 3-iminomorpholin-4-yl, 2-iminoimidazolidin-1-yl, 2-imino-1H-pyrazin-1-yl, 2,6-dioxopiperidin-1-yl, 2-oxopiperazin-1-yl, 2,6-dioxopiperazin-1-yl, 2,5-dioxopyrrolidin-1-yl, 2-oxo-1,3-oxazolidin-3-yl, 3-oxo-2H-pyridazin-2-yl, 2-caprolactam-1-yl (=2-oxoazepan-1-yl ), 2-azabicyclo[2.2.2]octan-3-on-2-yl, 5,6-dihydro-1H-pyrimidin-2-oxo-1-yl, 2-oxo-1,3-oxazinan-3-yl or 4H-1,4-oxazin-4-yl, A denotes H, unbranched, branched or cyclic alkyl having 1-10 C atoms, Ph denotes phenyl, Hal denotes F, Cl, Br or I, n denotes 1, 2, 3, 4, 5 or 6, m denotes 0, 1 or 2, and pharmaceutically usable salts or stereoisomers thereof, including mixtures thereof in all ratios.
 2. Compounds according to claim 1, in which R¹ denotes alkyl having 1, 2, 3, 4, 5 or 6 C atoms, which may be substituted by ethynyl, phenyl, OA, OH or OA, or pharmaceutically usable salts or stereoisomers thereof, including mixtures thereof in all ratios.
 3. Compounds according to claim 1, in which R³ denotes 2-oxopiperidin-1-yl, 2-oxopyrrolidin-1-yl, 2-oxo-1H-pyridin-1-yl, 3-oxomorpholin-4-yl, 4-oxo-1H-pyridin-1-yl, 2-oxo-1H-pyrazin-1-yl, 2-oxoimidazolidin-1-yl, 2-iminopiperidin-1-yl, 2-iminopyrrolidin-1-yl, 3-iminomorpholin-4-yl, 2-iminoimidazolidin- 1-yl, 2-imino-1H-pyrazin-1-yl, 2-oxopiperazin-1yl or 3-oxo-2H-pyridazin-2-yl, or pharmaceutically usable salts or stereoisomers thereof, including mixtures thereof in all ratios.
 4. Compounds according to claim 1, in which R² denotes H, methyl or F, or pharmaceutically usable salts or stereoisomers thereof, including mixtures thereof in all ratios.
 5. Compounds according to claim 1, in which Het denotes thienyl, furyl, pyrrolyl, benzofuranyl, benzo[b]thienyl, thiazolyl or oxazolyl, each of which is mono- or disubstituted by Hal, and pharmaceutically usable salts or stereoisomers thereof, including mixtures thereof in all ratios.
 6. Compounds according to claim 1, in which Het denotes thienyl, furyl, pyrrolyl, benzofuranyl, benzo[b]thienyl, thiazolyl or oxazolyl, each of which is mono- or disubstituted by Hal, R¹ denotes alkyl having 1, 2, 3, 4, 5 or 6 C atoms, which may be substituted by ethynyl, phenyl, OA, OH or OA, R² denotes H, Hal or A, R³ denotes 2-oxopiperidin-1-yl, 2-oxopyrrolidin-1-yl, 2-oxo-1H-pyridin-1-yl, 3-oxomorpholin-4-yl, 4-oxo-1H-pyridin-1-yl, 2-oxo-1H-pyrazin-1-yl, 2-oxoimidazolidin-1-yl, 2-iminopiperidin-1-yl, 2-iminopyrrolidin-1-yl, 3-iminomorpholin-4-yl, 2-iminoimidazolidin- 1-yl, 2-imino-1H-pyrazin-1-yl, 2-oxopiperazin-1-yl or 3-oxo-2H-pyridazin-2-yl, A denotes H, unbranched, branched or cyclic alkyl having 1-10 C atoms, Ph denotes phenyl, Hal denotes F, Cl, Br or I, n denotes 1, 2, 3, 4, 5 or 6, m denotes 0, 1 or 2, or pharmaceutically usable salts or stereoisomers thereof, including mixtures thereof in all ratios.
 7. Compounds according to claim 1 of the formula 1-(5-chlorothien-2-ylcarbonyl)-4-[4-(3-oxomorpholin-4-yl)phenyl]-2-propylsemicarbazide, 1-(5-chlorothien-2-ylcarbonyl)-4-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]-2-(prop-2-ynyl)semicarbazide, 1-(3-chlorothien-2-ylcarbonyl)-4-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]-2-benzylsemicarbazide, 1-(5-bromothien-2-ylcarbonyl)-4-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]-2-benzylsemicarbazide, 1-(3-chlorobenzo[b]thienyl-2-ylcarbonyl )-4-[3-methyl-4-(3-oxomorpholin-4-yl)-phenyl]-2-benzylsemicarbazide, 1-(5-chlorothien-2-ylcarbonyl)-4-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]-2-benzylsemicarbazide, 1-(5-bromothien-2-ylcarbonyl)-4-[3-fluoro-4-(3-oxomorpholin-4-yl)phenyl]-2-(2-methoxyethyl)semicarbazide, 1-(3-chlorobenzo[b]thienyl-2-ylcarbonyl)-4-[3-fluoro-4-(3-oxomorpholin-4-yl)-phenyl]-2-(2-methoxyethyl)semicarbazide, 1-(3-chlorothien-2-ylcarbonyl)-4-[3-fluoro-4-(3-oxomorpholin-4-yl)phenyl]-2-(2-methoxyethyl)semicarbazide, 1-(5-chlorothien-2-ylcarbonyl)-4-[3-fluoro-4-(3-oxomorpholin-4-yl)phenyl]-2-(2-methoxyethyl)semicarbazide, 1-(3-chlorothien-2-ylcarbonyl)-4-[4-(2-oxo-1H-pyrazin-1-yl)phenyl]-2-cyclopropylmethylsemicarbazide, 1-(3-chlorothien-2-ylcarbonyl)-4-[4-(2-oxo-1H-pyridin-1-yl)phenyl]-2-cyclopropylmethylsemicarbazide, 1-(3-chlorothien-2-ylcarbonyl)-4-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]-2-cyclopropylmethylsemicarbazide, 1-(5-chlorothien-2-ylcarbonyl)-4-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]-2-(2-methoxyethyl)semicarbazide, 1-(5-chlorothien-2-ylcarbonyl)-4-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]-2-cyclopropylmethylsemicarbazide, 1-(5-bromothien-2-ylcarbonyl)-4-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]-2-cyclopropylmethylsemicarbazide, or pharmaceutically usable salts or stereoisomers thereof, including mixtures thereof in all ratios.
 8. Process for the preparation of compounds of the formula I according to claim 1 or pharmaceutically usable salts or stereoisomers thereof, comprising reacting a) a compound of the formula II

in which R¹R² and R³ have the meaning indicated in claim 1, with a compound of the formula III Het-CO-L  III in which L denotes Cl, Br, I or a free or reactively functionally modified OH group, and Het has the meaning indicated in claim 1, and/or converting a base or acid of the formula I into one of its salts.
 9. A method of inhibiting coagulation factor Xa, comprising administering to a host in need thereof, a compound of the formula I according to claim
 1. 10. A method of inhibiting coagulation factor VIIa, comprising administering to a host in need thereof, a compound of the formula I according to claim
 1. 11. A pharmaceutical composition comprising at least one compound of the formula I according to claim 1 and/or pharmaceutically usable salts or stereoisomers thereof, including mixtures thereof in all ratios, and pharmaceutically acceptable excipients and/or adjuvants.
 12. A pharmaceutical composition according to claim 11, further comprising at least one further medicament active ingredient.
 13. Set (kit) consisting of separate packs of (a) an effective amount of a compound of the formula I according to claim 1 and/or pharmaceutically usable salts or stereoisomers thereof, including mixtures thereof in all ratios, and (b) an effective amount of a further medicament active ingredient.
 14. A method for the treatment of thrombosis, comprising administering to a host in need thereof, an effective amount of a compound of claim 1, or pharmaceutically usable salts or stereoisomers thereof, including mixtures thereof in all ratios. 